These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 11399981

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, COPHAR2- ANRS Study Group.
    Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
    [Abstract] [Full Text] [Related]

  • 4. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
    Fang AF, Damle BD, LaBadie RR, Crownover PH, Hewlett D, Glue PW.
    Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
    [Abstract] [Full Text] [Related]

  • 5. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH.
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [Abstract] [Full Text] [Related]

  • 6. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
    Khaliq Y, Gallicano K, Seguin I, Fyke K, Carignan G, Bulman D, Badley A, Cameron DW.
    Br J Clin Pharmacol; 2000 Aug; 50(2):108-15. PubMed ID: 10930962
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
    Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, Roda R, Sacchelli L, Gatti F, Delle Foglie P, Nardini G, Fabris P, Mori F, Castelli P, Testa L.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):643-9. PubMed ID: 15673746
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM.
    Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS study group.
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [Abstract] [Full Text] [Related]

  • 12. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
    Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
    [Abstract] [Full Text] [Related]

  • 13. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
    Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM, COPHAR1-ANRS 102 Study Group.
    Clin Pharmacokinet; 2005 Apr; 44(12):1267-78. PubMed ID: 16372824
    [Abstract] [Full Text] [Related]

  • 14. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S.
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [Abstract] [Full Text] [Related]

  • 15. The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.
    Jensen-Fangel S, Justesen US, Black FT, Pedersen C, Obel N.
    HIV Med; 2003 Jan; 4(1):48-52. PubMed ID: 12534959
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
    Bergshoeff AS, Wolfs TF, Geelen SP, Burger DM.
    Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
    [Abstract] [Full Text] [Related]

  • 20. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.
    Kattel K, Evande R, Tan C, Mondal G, Grem JL, Mahato RI.
    Br J Clin Pharmacol; 2015 Aug; 80(2):267-75. PubMed ID: 25752914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.